Literature DB >> 3156644

Inhibition by medroxyprogesterone acetate of precancerous mammary hyperplastic alveolar nodule formation in mice.

H Nagasawa, M Fujii, K Hagiwara.   

Abstract

The effects of medroxyprogesterone acetate (MPA) on precancerous mammary hyperplastic alveolar nodule (HAN) formation in mice were studied as a possible step to evaluate the anticarcinogenic role of MPA in mammary tumors. One month of subcutaneous pellet implantation of MPA to 6-7 month-old SHN breeding mice resulted in marked decrease and increase in the numbers of HAN and ghosts (the remnants of regressed HAN), respectively. The number of HAN still tended to be smaller in the experimental mice than in the control even 1 month after removal of MPA pellets which had been implanted for 2 months. Serum prolactin level at autopsy was apparently decreased and prolonged estrous vaginal smears observed in the control were replaced by diestrus in the experimental mice. All results indicate that MPA can lastingly inhibit HAN formation in mice, and suggest that MPA acts on mammary glands both directly and indirectly through its antiestrogenic effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156644     DOI: 10.1007/bf01807647

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.

Authors:  W Mattsson
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1978

2.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 3.  Treatment of advanced breast cancer with progestins.

Authors:  J Løber; C Rose; M Salimtschik; H T Mouridsen
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

4.  Inhibitory effects of potassium thiocyanate on normal and neoplastic mammary development in female mice.

Authors:  H Nagasawa; R Yanai; Y Nakajima; H Namiki; S Kikuyama; K Shiota
Journal:  Eur J Cancer       Date:  1980-04       Impact factor: 9.162

5.  Prolactin and murine mammary tumorigenesis: a review.

Authors:  C W Welsch; H Nagasawa
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

6.  Effects of progesterone on mammary carcinogenesis when various doses of DMBA were applied directly to rat mammae.

Authors:  A G Jabara; P S Anderson
Journal:  Pathology       Date:  1982-07       Impact factor: 5.306

7.  Two-way selection of a stock of Swiss albino mice for mammary tumorigenesis: establishment of two new strains (SHN and SLN).

Authors:  H Nagasawa; R Yanai; H Taniguchi; R Tokuzen; W Nakahara
Journal:  J Natl Cancer Inst       Date:  1976-08       Impact factor: 13.506

8.  Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.

Authors:  M Izuo; Y Iino; K Endo
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

  8 in total
  3 in total

1.  Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.

Authors:  E Kordon; C Lanari; R Meiss; P Elizalde; E Charreau; C Dosne Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

2.  Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

Authors:  H Nagasawa; M Aoki; N Sakagami; M Ishida
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

3.  Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis.

Authors:  K Niwa; S Morishita; T Murase; N Itoh; T Tanaka; H Mori; T Tamaya
Journal:  Jpn J Cancer Res       Date:  1995-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.